uniQure N.V. $QURE Position Raised by Nantahala Capital Management LLC

Key Points

• Nantahala Capital Management LLC increased its stake in uniQure N.V. by 3.8%, holding approximately $29.21 million worth of shares, making it the 12th largest holding in its portfolio.
• Several institutional investors, including RTW Investments LP and Point72 Asset Management, significantly increased their positions in uniQure during the fourth quarter, contributing to institutional investors owning 78.83% of the company's stock.
• Analysts have upgraded uniQure's stock rating, with price targets set as high as $70.00, indicating strong market confidence despite the company reporting a negative EPS and revenue of $5.26 million last quarter.

Nantahala Capital Management LLC boosted its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 3.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,755,962 shares of the biotechnology company's stock after purchasing an additional 101,598 shares during the period. uniQure makes up about 1.2% of Nantahala Capital Management LLC's investment portfolio, making the stock its 12th biggest holding. Nantahala Capital Management LLC owned approximately 5.03% of uniQure worth $29,213,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Aberdeen Group plc increased its holdings in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after purchasing an additional 706,216 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Integral Health Asset Management LLC increased its holdings in uniQure by 175.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $19,426,000 after purchasing an additional 700,000 shares in the last quarter. RTW Investments LP increased its holdings in uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after purchasing an additional 893,625 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in uniQure by 9.2% in the 4th quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company's stock valued at $15,521,000 after purchasing an additional 73,988 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on QURE shares. Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of uniQure in a report on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Chardan Capital restated a "buy" rating and set a $35.00 target price on shares of uniQure in a research note on Friday, August 29th. Cantor Fitzgerald set a $47.00 target price on uniQure in a research note on Wednesday, July 30th. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $37.45.

uniQure Stock Up 2.0%

NASDAQ:QURE traded up $0.35 during mid-day trading on Thursday, reaching $17.73. The stock had a trading volume of 976,912 shares, compared to its average volume of 1,351,235. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The stock's 50 day simple moving average is $14.90 and its two-hundred day simple moving average is $13.77. uniQure N.V. has a 1-year low of $4.45 and a 1-year high of $19.18. The company has a market capitalization of $972.85 million, a price-to-earnings ratio of -4.52 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. Equities analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insider Buying and Selling

In other uniQure news, Director Robert Gut sold 3,336 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $48,205.20. Following the completion of the transaction, the director directly owned 56,879 shares in the company, valued at $821,901.55. The trade was a 5.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director directly owned 34,190 shares in the company, valued at approximately $494,045.50. This trade represents a 5.82% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock valued at $322,426 over the last 90 days. 4.79% of the stock is owned by corporate insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.